PCM
DGX icon

Prelude Capital Management’s Quest Diagnostics DGX Stock Holding History

Prelude Capital Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-8,500
Closed -$1.28M – 1265
2024
Q4 		$1.28M Buy
+8,500
New +$1.32M 0.08% 310
2014
Q2 		– Sell
-4,000
Closed -$232K – 1963
2014
Q1 		$232K Buy
+4,000
New +$214K 0.03% 678

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Prelude Capital Management's DGX Position: Q1 2026 in Review

Prelude Capital Management sold out of Quest Diagnostics (DGX) in Q1 2026, closing a stake of 6,886 shares — an estimated $1.19M sold.

Prelude Capital Management first reported a position in DGX in Q3 2013 and held it in 22 quarters. The position peaked at $3.74M in Q4 2017. 1,065 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Prelude Capital Management reported no remaining Quest Diagnostics position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 6,886 Quest Diagnostics shares in Q1 2026, an estimated $1.19M.
  • Prelude Capital Management first reported a position in Quest Diagnostics in Q3 2013 and held it in 22 quarters.
  • Prelude Capital Management's Quest Diagnostics position peaked at $3.74M in Q4 2017.
  • 1,065 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.